SynOx Therapeutics Ltd.

Following a couple of fairly disastrous trial failures, Merck KGaA can finally celebrate a hit. The colony stimulating factor-1 (CSF-1) inhibitor pimicotinib, originated by China-based Abbisko and lic

TRex Bio Inc. (TRexBio) announced an $84m series B venture capital round on 13 November that it will use to develop lead drug candidate TRB-061, a TNFR2 agonist, through early clinical proof-of-concep

The cash keeps coming into SynOx Therapeutics Ltd. , with the Ireland-domiciled biotech securing over $100m in the past week to push its late-stage asset emactuzumab over the regulatory finishing lin

With sentiment turning against the biotech sector in the public markets, leading European life science venture capital firm Forbion has put together a new fund that could be worth €600m to tap into so